
The demand for obesity drug Wegovy in the US has taken Novo Nordisk by surprise, and the pharmaceutical company is struggling to keep up, acknowledged CEO Lars Fruergaard Jørgensen in the second quarter report released a few weeks ago.
Now, however, Danish business media Børsen reports that the pharma company cannot foresee supply stabilizing until 2022, confirmed in a product supply update by Novo Nordisk.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app